| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
78 |
| Employees |
354 |
| Revenues (TTM) (Millions $) |
121 |
| Net Income (TTM) (Millions $) |
-284 |
| Cash Flow (TTM) (Millions $) |
61 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Portola Pharmaceuticals Inc. is a biotechnology company headquartered in South San Francisco, California. The company is focused on developing and commercializing novel therapeutics for the treatment of life-threatening thrombosis and hematologic disorders. The company was founded in January 2003 and has been publicly traded on the NASDAQ stock exchange since 200
Portolaes proprietary pipeline includes four investigational drugs in various stages of development. Betrixaban is an oral, once-daily Factor Xa inhibitor that is being investigated for the prevention of venous thromboembolism (VTE) in acute medically ill patients. Cerdulatinib is a dual Syk/JAK kinase inhibitor being investigated for hematologic cancers such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Andexanet alfa is an anticoagulant reversal agent being developed to reverse the anticoagulant effects of Factor Xa inhibitors like betrixaban and apixaban. Syk inhibitor is part of the company's preclinical pipeline, which is being evaluated as a treatment for various autoimmune disorders.
In 2015, Portola received its first FDA approval for Bevyxxa (betrixaban). It is the first and only FDA-approved oral anticoagulant for the extended prevention of VTE in acute medically ill patients. In 2018, the company received its second FDA approval for Andexxa for the reversal of apixaban and rivaroxaban in life-threatening or uncontrolled bleeding.
Portola has partnerships with major pharmaceutical companies such as Pfizer, Bristol-Myers Squibb and Alexion Pharmaceuticals to further develop and commercialize its pipeline products. The company has a team of experienced scientists, researchers, and business professionals who are committed to discovering innovative treatments to improve patient outcomes worldwide.
Portola's core values include innovation, collaboration, integrity, respect, and excellence, which it believes are key to driving its efforts to develop transformative medicines that help save patients' lives. The company is dedicated to investing in science and technology to advance the fields of thrombosis and hematology, working to develop new solutions that can address unmet patient needs.
Company Address: 270 E. Grand Avenue South San Francisco 94080 CA
Company Phone Number: 246-7000 Stock Exchange / Ticker: NASDAQ PTLA
|
%